Amicogen Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Piao Zhe

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

No hay actualizaciones

Recent updates

Revenues Working Against Amicogen, Inc.'s (KOSDAQ:092040) Share Price

Nov 11

Little Excitement Around Amicogen, Inc.'s (KOSDAQ:092040) Revenues As Shares Take 27% Pounding

Jun 27

Does Amicogen (KOSDAQ:092040) Have A Healthy Balance Sheet?

Jun 19

Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 39%

Mar 21

Could The Market Be Wrong About Amicogen, Inc. (KOSDAQ:092040) Given Its Attractive Financial Prospects?

Jan 14

Amicogen (KOSDAQ:092040) Is Growing Earnings But Are They A Good Guide?

Dec 30

Is Now The Time To Put Amicogen (KOSDAQ:092040) On Your Watchlist?

Dec 15

Did You Miss Amicogen's (KOSDAQ:092040) 37% Share Price Gain?

Nov 30

CEO

Piao Zhe

no data

Permanencia

Piao Zhe serves as Chief Executive Officer at Amicogen, Inc.

Amicogen Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Recent updates

Enzynomics Co., Ltd. completed the acquisition of 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040).

Revenues Working Against Amicogen, Inc.'s (KOSDAQ:092040) Share Price

Amicogen, Inc. announced that it has received KRW 4 billion in funding from Kiwoom Securities Co., Ltd.

New major risk - Financial data availability

Little Excitement Around Amicogen, Inc.'s (KOSDAQ:092040) Revenues As Shares Take 27% Pounding

Does Amicogen (KOSDAQ:092040) Have A Healthy Balance Sheet?

Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 39%

New minor risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Share price stability

Amicogen, Inc. announced that it expects to receive KRW 40 billion in funding

Investor sentiment deteriorated over the past week

Amicogen, Inc. announced that it has received KRW 22.2724863 billion in funding from Lysando AG

Amicogen, Inc. (KOSDAQ:A092040) agreed to acquire a 30% stake in BIFIDO Co., Ltd (KOSDAQ:A238200) from a group of shareholders for KRW 60.1 billion.

Amicogen, Inc. announced that it expects to receive KRW 22.2724863 billion in funding from Lysando AG

Amicogen, Inc. announced that it has received KRW 50 billion in funding

Amicogen, Inc. announced that it expects to receive KRW 50 billion in funding from Samsung Securities Co., Ltd. and other investors

With EPS Growth And More, Amicogen (KOSDAQ:092040) Is Interesting

Investor sentiment improved over the past week

Should Amicogen (KOSDAQ:092040) Be Disappointed With Their 24% Profit?

New 90-day low: ₩29,700

Is Amicogen (KOSDAQ:092040) A Risky Investment?

New 90-day low: ₩31,700

What Kind Of Investors Own Most Of Amicogen, Inc. (KOSDAQ:092040)?

Could The Market Be Wrong About Amicogen, Inc. (KOSDAQ:092040) Given Its Attractive Financial Prospects?

Amicogen (KOSDAQ:092040) Is Growing Earnings But Are They A Good Guide?

Investor sentiment improved over the past week

Is Now The Time To Put Amicogen (KOSDAQ:092040) On Your Watchlist?

Did You Miss Amicogen's (KOSDAQ:092040) 37% Share Price Gain?

New 90-day high - ₩42,700

New 90-day high - ₩41,600

New 90-day high - ₩40,400

CEO

Permanencia